Shire PLC (SHPG) Stock Rating Reaffirmed by Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their hold rating on shares of Shire PLC (NASDAQ:SHPG) in a research note issued to investors on Friday, October 27th. Piper Jaffray Companies currently has a $160.00 target price on the biopharmaceutical company’s stock.

SHPG has been the topic of a number of other reports. Royal Bank Of Canada set a $213.00 price objective on shares of Shire PLC and gave the company a buy rating in a research report on Friday, August 4th. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a buy rating in a research report on Saturday, July 1st. BTIG Research reaffirmed a buy rating and issued a $242.00 target price on shares of Shire PLC in a research report on Monday, July 17th. Stifel Nicolaus reissued a buy rating and set a $245.00 price objective on shares of Shire PLC in a research report on Wednesday, July 12th. Finally, ValuEngine raised shares of Shire PLC from a hold rating to a buy rating in a research report on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $212.18.

Shares of Shire PLC (NASDAQ SHPG) opened at $139.27 on Friday. Shire PLC has a 1 year low of $137.17 and a 1 year high of $192.15. The stock has a market cap of $42,167.93, a P/E ratio of 9.65, a price-to-earnings-growth ratio of 0.78 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.64 by $0.17. Shire PLC had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $3.70 billion during the quarter. During the same quarter in the previous year, the firm posted $3.17 earnings per share. The company’s revenue was up 7.1% compared to the same quarter last year. equities research analysts anticipate that Shire PLC will post 15 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Shire PLC (SHPG) Stock Rating Reaffirmed by Piper Jaffray Companies” was originally reported by Week Herald and is owned by of Week Herald. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://weekherald.com/2017/11/15/shire-plc-shpg-earns-hold-rating-from-piper-jaffray-companies.html.

Large investors have recently added to or reduced their stakes in the company. Seizert Capital Partners LLC lifted its position in shares of Shire PLC by 13.3% during the third quarter. Seizert Capital Partners LLC now owns 10,786 shares of the biopharmaceutical company’s stock worth $1,652,000 after purchasing an additional 1,267 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Shire PLC by 2.9% during the third quarter. Fisher Asset Management LLC now owns 57,419 shares of the biopharmaceutical company’s stock worth $8,793,000 after purchasing an additional 1,619 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Shire PLC by 63.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 17,797 shares of the biopharmaceutical company’s stock worth $2,941,000 after purchasing an additional 6,917 shares during the last quarter. Baldwin Investment Management LLC lifted its position in shares of Shire PLC by 1.4% during the second quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 23 shares during the last quarter. Finally, Oak Ridge Investments LLC lifted its position in shares of Shire PLC by 3.2% during the second quarter. Oak Ridge Investments LLC now owns 81,011 shares of the biopharmaceutical company’s stock worth $13,389,000 after purchasing an additional 2,528 shares during the last quarter. Institutional investors and hedge funds own 18.27% of the company’s stock.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply